TGF-β / SMAD signalling: fibrosis, tissue repair, and peptide modulators

Detailed explanation

The transforming growth factor beta (TGF-β) superfamily comprises approximately 33 human ligands including the classical TGF-βs (TGF-β1, TGF-β2, TGF-β3), the bone morphogenetic proteins (BMPs), activins, inhibins, growth-and-differentiation factors (GDFs including GDF-8/myostatin), and additional ligands. This superfamily governs tissue development, homeostasis, and pathological remodelling through a conserved receptor-and-effector architecture in which ligand-receptor engagement drives SMAD transcription factor activation and consequent transcriptional responses. Canonical TGF-β signalling proceeds through the following steps. Latent TGF-β is stored in the extracellular matrix bound to latent TGF-β binding proteins (LTBPs) and requires activation — typically by integrin αvβ6 or αvβ8 binding, or by matrix-metalloproteinase-mediated cleavage — to release the active TGF-β dimer. Active TGF-β then binds the type II receptor (TGFβRII), which recruits and phosphorylates the type I receptor (TGFβRI, also known as ALK5). Activated TGFβRI phosphorylates receptor-associated SMADs (R-SMADs): SMAD2 and SMAD3 for classical TGF-β and activin signalling; SMAD1, SMAD5, and SMAD8 for BMP signalling. Phosphorylated R-SMADs bind the common SMAD4, translocate to the nucleus, and drive transcription of TGF-β-responsive genes including collagen type I, fibronectin, α-SMA (α-smooth-muscle actin, the marker of myofibroblast differentiation), and negative-feedback regulators SMAD6 and SMAD7. Non-canonical (non-SMAD) TGF-β signalling additionally engages the MAPK pathway (ERK, JNK, p38), PI3K/Akt, and RhoA/ROCK cytoskeletal signalling. These non-canonical arms contribute to fibroblast activation, EMT (epithelial-to-mesenchymal transition), and cytoskeletal reorganisation independent of SMAD transcription. Modern anti-fibrotic drug development explicitly considers both canonical and non-canonical arms as pharmacological targets. The fibroblast-to-myofibroblast transition (FMT) is the central pathological event driven by chronic TGF-β signalling in fibrotic tissue. Quiescent fibroblasts under TGF-β1 stimulation acquire contractile properties through α-SMA-containing stress fibre assembly, upregulate collagen and fibronectin production, resist apoptosis, and become the principal effectors of pathological matrix deposition. Myofibroblasts may derive from resident tissue fibroblasts, circulating fibrocytes, epithelial cells undergoing EMT, endothelial cells undergoing EndMT, or (in the kidney) tubular epithelial cells. Persistent myofibroblast populations drive fibrosis progression; myofibroblast clearance through apoptosis or reverse-EMT is central to fibrosis resolution. Multiple research peptides modulate the TGF-β/SMAD axis. AC-SDKP (Ac-Ser-Asp-Lys-Pro, Goralatide, the TB-500 fragment) suppresses TGF-β1-driven SMAD3 nuclear translocation, reduces α-SMA and collagen expression in cardiac and renal fibroblasts, and attenuates macrophage-to-myofibroblast transition. Its degradation by angiotensin-converting enzyme (ACE) explains part of the anti-fibrotic benefit of ACE-inhibitor therapy in cardiovascular and renal disease. GHK-Cu suppresses TGF-β1-driven SMAD2/3 phosphorylation in pulmonary and hepatic fibroblasts and favours organised mature collagen deposition over disordered collagen-III accumulation. BPC-157 contributes indirect anti-fibrotic activity through reduction of TNF-α, IL-1β, and IL-6 signalling that would otherwise drive fibroblast recruitment and activation; the anti-inflammatory mechanism attenuates the fibrosis-inducing inflammatory phase rather than directly suppressing SMAD signalling. Follistatin acts at the ligand level — directly binding and sequestering activins and myostatin (GDF-8), preventing productive receptor engagement. This ligand-sequestration mechanism differs from downstream SMAD suppression and provides pharmacological selectivity for specific TGF-β family members. The myostatin-inhibitor branch of follistatin's activity has driven muscle-hypertrophy clinical development (ACE-083 in Duchenne muscular dystrophy). Bimagrumab (a monoclonal antibody rather than peptide) targets the type II activin receptor (ActRIIB), blocking receptor-level ligand binding as an alternative anti-TGF-β strategy. Standard research assays for TGF-β/SMAD pharmacology include Western blot for phospho-SMAD2 (Ser465/467) and phospho-SMAD3 (Ser423/425); immunofluorescence for nuclear SMAD3 translocation; α-SMA immunostaining as myofibroblast marker; hydroxyproline assay for total collagen; Masson's trichrome and Sirius red histology for fibrosis architecture; and Ashcroft scoring in bleomycin-induced murine pulmonary fibrosis. Reporter cell lines with SMAD-responsive elements (SBE, CAGA) provide quantitative TGF-β signalling readouts. TGF-β1 measurement in tissue homogenates, bronchoalveolar lavage, or serum by ELISA supports mechanistic characterisation.